Group 1: Macroeconomic Insights - The U.S. Congress passed a fiscal and tax reform reconciliation bill, projected to increase government debt by $2.4 trillion over the next decade, with current debt exceeding $36 trillion[3] - The market sentiment is mixed due to concerns over the deficit, leading to a further decline in the U.S. dollar index[9] - Historical data indicates that during dollar depreciation phases, non-U.S. equities tend to outperform U.S. equities, and commodities like copper, gold, and oil show upward trends[9] Group 2: Trade and Tariff Developments - President Trump threatened a 50% tariff on EU goods starting June 1, with the implementation deadline pushed to July 9 after negotiations[2] - The ongoing tariff discussions are seen as part of Trump's negotiation strategy rather than a definitive policy shift[2] - The focus is shifting from tariffs to fiscal stimulus, although concerns about the deficit complicate market reactions[9] Group 3: Economic Indicators - The U.S. initial jobless claims for the week ending May 24 are projected at 227,000[23] - The April core PCE price index year-on-year is reported at 2.5%, indicating a slight decrease from previous levels[23] - The U.S. housing market shows signs of recovery, with a 6.1% increase in the April pending home sales index[23]

Investment Rating - The investment rating for the company is "Buy" and is maintained [1] Core Insights - The company is successfully advancing its new product, Lulule Herbal Health Water, which is positioned in a rapidly growing health beverage market. The competitive landscape is favorable, providing valuable development opportunities. The chairman is personally leading the product development and marketing efforts, indicating the company's commitment to this new line [3][4] - The company is expanding its presence in the southern market by establishing a factory and creating new sales districts. Adjustments to product formulations are being considered to cater to regional taste preferences. The introduction of new products is expected to enhance market penetration and address weaknesses in the southern market [4] - Cost reductions in key raw materials are expected to improve profit margins. The price of wild apricot kernels, a significant ingredient, is projected to decrease, contributing to cost savings and supporting market investments and new product promotions [4] - The company anticipates steady growth in its core product, Almond Milk, with expected revenue of 34.52 billion, 38.02 billion, and 40.07 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 5.01%, 10.14%, and 5.39%. The net profit attributable to the parent company is projected to be 7.14 billion, 7.81 billion, and 8.13 billion yuan for the same years, with corresponding growth rates of 7.15%, 9.46%, and 4.01% [5][8][10] Company Overview - The latest closing price of the company's stock is 10.54 yuan, with a total market capitalization of 111 billion yuan. The company has a debt-to-asset ratio of 25.1% and a price-to-earnings ratio of 16.47 [2]

Investment Rating - The investment rating for the company is "Buy" and is maintained [1] Core Views - The company is successfully advancing its new product, Lulule Herbal Health Water, which is positioned in a rapidly growing health beverage market. The competitive landscape is favorable, providing valuable development opportunities. The chairman is personally leading the product development and marketing efforts, indicating the company's commitment to this new line [3][4] - The company is expanding its presence in the southern market by establishing a factory and creating new sales districts. Adjustments to product formulations are being considered to cater to regional taste preferences. The introduction of new products is expected to enhance market penetration and address weaknesses in the southern market [4] - Cost reductions in key raw materials are expected to improve profit margins. The price of wild apricot kernels, a significant ingredient, is projected to decrease, contributing to cost savings and supporting market investments and new product promotions [4] - The company anticipates steady growth in its core product, Almond Milk, with a recovery expected in Q2 due to resilient demand. Revenue projections for 2025-2027 are set at 34.52 billion, 38.02 billion, and 40.07 billion yuan, respectively, with corresponding net profits of 7.14 billion, 7.81 billion, and 8.13 billion yuan [8][10] Summary by Sections Company Overview - The latest closing price is 10.54 yuan, with a total market capitalization of 111 billion yuan. The company has a debt-to-asset ratio of 25.1% and a price-to-earnings ratio of 16.47 [2] Financial Forecast and Key Metrics - Revenue is projected to grow at rates of 5.01%, 10.14%, and 5.39% for the years 2025, 2026, and 2027, respectively. The net profit is expected to grow by 7.15%, 9.46%, and 4.01% in the same years. The earnings per share (EPS) is forecasted to be 0.68, 0.74, and 0.77 yuan for 2025, 2026, and 2027, respectively [10][11]

发布时间：2025-05-26 证券研究报告：固定收益报告 研究所 分析师:梁伟超 SAC 登记编号:S1340523070001 Email:liangweichao@cnpsec.com 分析师:崔超 SAC 登记编号:S1340523120001 Email:cuichao@cnpsec.com 近期研究报告 《【中邮固收】城投 2024 年报全梳理 20250521》 - 2025.05.22 固收周报 生产热度回落，物价整体走低 ——高频数据跟踪 20250526 核心观点 高频经济数据关注点：第一，生产热度整体回落，焦炉、高炉、 沥青、PX、PTA、全钢胎、半钢胎开工率均下降，螺纹钢产量低位回 升。第二，商品房成交面积减少，城市土地供应面积增加。第三，物 价整体下降，原油、焦煤、螺纹钢、铝价下跌，铜、锌价格上涨，农 产品价格整体下降。第四，国内航运指数回升，BDI 指数下降。短期 重点关注新一轮稳增长刺激政策落地、房地产市场恢复情况及美国关 税政策变动影响。 生产：热度整体回落 5 月 23 日当周，焦炉产能利用率下降 0.05 pct，高炉开工率下 降 0.46 pct，螺纹钢产量增加 4.95 ...

证券研究报告：固定收益报告 发布时间：2025-05-26 研究所 分析师:梁伟超 SAC 登记编号:S1340523070001 Email:liangweichao@cnpsec.com 近期研究报告 《【中邮固收】城投 2024 年报全梳理 20250521》 - 2025.05.22 固收周报 存单利率下不来怎么看？ ——流动性周报 20250525 ⚫ 1.6%或是资金充分下行后，NCD 的合理定价中枢位置 降准资金落地后，资金边际有所波动，同业存单利率未再下行， 加重了机构对流动性的担忧。 与往年不同，当前银行缺的主要是短期负债。从广义负债缺口来 看，贷款与存款的增速在年初至今已经明显收敛。从大行流动性稳定 指标来看，银行长期负债压力并不大。年初以来，大行负债压力的主 要来源是非银存款流失产生的缺口，非银存款本身期限也相对较短， 替代的 NCD 融资期限需求也相对较短。 同业存单发行短期化，也就造成其负债重置周期缩短。一季度供 需两端在期限方面达成共识，3 月的发行高峰以短期化为主，这也造 成到期量在短期的激增，6 月份到期规模在历史新高的 4 万亿以上。 所以，5 月中下旬之后，同业存单利率下不 ...

证券研究报告：国防军工|行业周报 行业投资评级 强于大市|维持 研究所 分析师:鲍学博 SAC 登记编号:S1340523020002 Email:baoxuebo@cnpsec.com 分析师:王煜童 SAC 登记编号:S1340523070004 Email:wangyutong@cnpsec.com 近期研究报告 | 行业基本情况 | | | --- | --- | | 收盘点位 | 1471.28 | | 52 周最高 | 1712.48 | | 52 周最低 | 1113.62 | 《中邮军工-军工 AI 深度：AI 迎来奥本 海默时刻，将改变未来战争形态》 - 2025.05.22 行业相对指数表现 国防军工行业报告 -13% -8% -3% 2% 7% 12% 17% 22% 27% 32% 2024-05 2024-08 2024-10 2024-12 2025-03 2025-05 国防军工 沪深300 美国防预算将达 1 万亿美元，创历史新高 资料来源：聚源，中邮证券研究所 投资要点 据美媒报道，美国白宫及国防部近日宣称，美国 2026 财年国防 预算将首次达到 1 万亿美元。若获国会批准 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The company focuses on three core businesses: "Perception, Connection, and Intelligent Manufacturing," targeting the new energy vehicle and digital empowerment sectors. It aims to innovate continuously based on customer needs and integrate into national strategies and industry developments [4]. - For 2024, the company is projected to achieve revenue of 11.709 billion yuan, a year-on-year increase of 13.57%, and a net profit attributable to shareholders of 1.221 billion yuan, up 21.17% year-on-year. The growth is driven by the demand for intelligent manufacturing and connection services, particularly in the AIGC application field [4][5]. - The company maintains a global leadership position in thermal management for new energy vehicles and multifunctional sensor technology, with significant revenue contributions from its sensor business [4]. Financial Projections - Revenue projections for 2025, 2026, and 2027 are 16.275 billion yuan, 20.012 billion yuan, and 23.577 billion yuan, respectively. Corresponding net profits are expected to be 1.701 billion yuan, 2.179 billion yuan, and 2.716 billion yuan [9][11]. - The current stock price corresponds to a price-to-earnings (P/E) ratio of 25 times for 2025, 19 times for 2026, and 16 times for 2027 [9]. Business Developments - The company plans to establish a joint venture with Lika Precision to enhance its capabilities in 3D printing, focusing on SLM manufacturing technology for various applications [6][8]. - The connection business is experiencing explosive growth, particularly in domestic and overseas markets, with significant demand for optical modules [5][6]. Market Performance - The company's stock has shown a positive trend, with a notable increase in performance over the past year, reflecting strong market confidence [7].

Industry Investment Rating - The industry investment rating is "Outperform" [2] Core Viewpoints - The report highlights that the recent licensing deal between 3SBio and Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707 marks a record in overseas transactions for Chinese innovative pharmaceutical companies, indicating a potential surge in licensing out activities [5][13] - The global market for bispecific antibodies is projected to exceed $80 billion by 2030, with PD-1/VEGF bispecifics being a focal point for multinational pharmaceutical companies [20] - In 2024, the total licensing out amount for Chinese innovative drugs surpassed $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total [23] Summary by Sections Weekly Insights - 3SBio's licensing agreement with Pfizer involves an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion, along with a tiered sales revenue share [13][14] - The report notes that the biopharmaceutical sector has seen a weekly increase of 1.78%, outperforming the CSI 300 index by 1.96 percentage points [24][29] Subsector Performance - The report details that the biopharmaceutical sector's performance is diverse, with the other bioproducts sector showing the highest increase of 4.09%, while the hospital sector experienced the largest decline of 1.07% [6][28] Recommended and Benefiting Stocks - Recommended stocks include Weikang Medical, Maipu Medical, and Yifeng Pharmacy, among others [7][40] - Benefiting stocks from the recent trends include Hualan Biological Engineering, BGI Genomics, and Mindray Medical [7][45] Market Trends - The report emphasizes the acceleration of licensing out activities for Chinese pharmaceutical companies, with a notable increase in both the number and value of transactions in recent years [23][25] - The report suggests that the medical device sector is expected to see significant growth due to policy changes and increased procurement activities [31]

Investment Rating - The industry investment rating is "Outperform" [2] Core Insights - The report highlights that the recent licensing deal between 3SBio and Pfizer for the PD-1/VEGF bispecific antibody SSGJ-707 marks a record in overseas transactions for Chinese innovative pharmaceutical companies, indicating a potential surge in licensing out activities [5][13] - The global market for bispecific antibodies is projected to exceed $80 billion by 2030, with PD-1/VEGF bispecifics being a focal point for multinational pharmaceutical companies [5][20] - In 2024, the total amount of licensing out agreements for Chinese innovative drugs surpassed $51.9 billion, a year-on-year increase of 27.4%, accounting for 30% of the global total [5][23] Industry Performance - The pharmaceutical sector saw an increase of 1.78% this week, outperforming the CSI 300 index by 1.96 percentage points, ranking first among 31 sub-industries [24][29] - The biopharmaceutical sector experienced the highest growth this week, with a rise of 4.09% [6][28] Subsector Highlights - The report identifies several subsectors with notable performance: - Other biopharmaceuticals increased by 4.09% - Raw materials and medical research outsourcing sectors also saw increases of 4.03% and 3.6% respectively [6][28] - The report recommends several stocks, including Weikang Medical, Maipu Medical, and Yifeng Pharmacy, as potential beneficiaries of the current market dynamics [7][40] Clinical Development - SSGJ-707 has shown promising clinical data, with an overall response rate (ORR) of 70.8% in PD-1 positive NSCLC patients and a disease control rate (DCR) of 100% [17][20] - The drug is currently in Phase III clinical trials and has received breakthrough therapy designation in China [16][20] Market Trends - The report notes a significant trend towards the licensing out of innovative drugs from China, with the number of transactions increasing from 3% in 2019 to 13% in 2024 [23] - The report emphasizes the importance of AI and other technological advancements in driving growth within the medical device and pharmaceutical sectors [30][36]

Market Performance Review - The A-share market continued a pattern of rising and then falling, with a defensive style prevailing. Most major indices declined, with the CSI A50 being the only major index to rise. The large-cap indices, such as the CSI 300 and SSE 50, experienced smaller declines, while the STAR 50 and CSI 1000 saw larger drops [12][15] - The sector rotation remained rapid, with pharmaceuticals, comprehensive sectors, non-ferrous metals, automobiles, and home appliances leading the gains. In contrast, beauty care, non-bank financials, and retail sectors, which had performed well the previous week, saw significant declines [15][28] A-share High-Frequency Data Tracking - The personal investor sentiment index showed a continued decline, with the 7-day moving average reported at -8.0% as of May 23, slightly up from -9.9% on May 17, but still in a negative range, indicating a lack of confidence in the overall A-share market [4][17] - Financing activity remained stagnant, with net purchases maintaining stability and the proportion of financing transactions slightly decreasing, reflecting the low enthusiasm among personal investors [20][21] Future Outlook and Investment Views - The A-share market is expected to remain in a volatile pattern due to a lack of breakthrough opportunities. Although the recent phase of the US-China trade war has yielded some positive results, it reduces the necessity for large-scale domestic stimulus policies, delaying the expected policy window until late July [28][30] - The report suggests that the current market index has rebounded to levels seen before the US-China trade war 2.0, indicating that further upward movement requires new catalysts to boost market confidence [28][30] Configuration Aspects - The report highlights that the recent interest rate cuts and reserve requirement ratio reductions enhance the cost-effectiveness of dividend stocks. It recommends focusing on pure dividend stocks such as banks, railways, and power sectors, while waiting for clear domestic stimulus policies to catalyze consumer stocks [5][30]